Covestor’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$0 Sell
28
-18
-39% – ﹤0.01% 2798
2026
Q2
$0 Buy
46
+39
+557% – ﹤0.01% 2817
2026
Q1
$0 Hold
7
– – ﹤0.01% 2734
2025
Q4
$0 Sell
7
-1
-13% – ﹤0.01% 2707
2025
Q3
$0 Hold
8
– – ﹤0.01% 2736
2025
Q2
$0 Hold
8
– – ﹤0.01% 2722
2025
Q1
$0 Hold
8
– – ﹤0.01% 2692
2024
Q4
$0 Sell
8
-3
-27% – ﹤0.01% 2701
2024
Q3
$0 Sell
11
-1
-8% – ﹤0.01% 2724
2024
Q2
$0 Buy
+12
New – ﹤0.01% 2717

Other funds holding SPRY

Covestor's SPRY Position: Q3 2026 in Review

Covestor reduced its ARS Pharmaceuticals (SPRY) stake by 39% in Q3 2026, cutting 18 shares and leaving 28 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Covestor first reported a position in SPRY in Q2 2024 and has held it in 10 quarters since. 191 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Covestor held 28 shares of ARS Pharmaceuticals worth $0 as of Q3 2026.
  • Covestor sold 18 ARS Pharmaceuticals shares in Q3 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2798 holding.
  • Covestor first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • 191 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.